BioSpace News Archive

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, presents six posters detailing research data from its proprietary gene therapy platform at the American Society of Gene and Cell Therapy Annual Meeting 2021, taking place May 11-14, 2021.

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced results for the first quarter ended March 31, 2021 and provided a business update.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study of its re-purposed drug NP-120.

Results Provide New Evidence of the Recommended Formula Determined in the AREDS2 Study

GO2 Foundation for Lung Cancer has launched a landmark initiative to identify the needs of the Small Cell Lung Cancer community.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that Eran Ophir, Ph.D., Vice President Research and Drug Discovery at Compugen, will participate at the Society for Immunotherapy of Cancer Targets for Cancer Immunotherapy: A Deep Dive Seminar Series.

Samus Therapeutics, Inc., a privately held, Boston-based biopharmaceutical company developing epichaperome inhibitors to treat CNS diseases and hematologic malignancies, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to develop PU-AD for the treatment of recurrent malignant glioma.

Ginkgo is building the leading horizontal platform for synthetic biology, making it possible to program cells as easily as we can program computers and enabling innovation across industries, including therapeutics, industrials, food and agriculture

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced the Company will host a conference call reviewing the first quarter highlights at 8:00 a.m. ET on Thursday, May 13th, 2021.